| abstract |
The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like. A compound represented by the formula (I): wherein R1 is an optionally substituted 4- to 7-membered nitrogen-containing heterocyclic group, optionally substituted carbamoyl, or optionally substituted sulfamoyl; R2 is optionally substituted alkyl, optionally substituted alkoxy, an optionally substituted 3- to 7-membered cyclic group, —SR′, —SOR′, or —SO2R′ (R′ is a substituent); R3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, —O-Cy (Cy is an optionally substituted 3- to 7-membered cyclic group which may be condensed with benzene), —SR″, —SOR″, or —SO2R″ (R″ is a substituent), or an optionally substituted 3- to 7-membered cyclic group which may be condensed with benzene; R4 is hydrogen, or optionally substituted alkyl; provided that when R3 is hydrogen, halogen, or methoxy, then R2 is not optionally substituted alkyl, or optionally substituted alkoxy; further provided that 5-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furyl)pyridin-3-yl]-N-pyridin-4-yl-1H-indazol-3-amine and 5-[5-{[(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furyl)pyridin-3-yl]-1-(4-methoxybenzyl)-N-pyridin-4-yl-1H-indazol-3-amine are excluded; or a salt thereof. |